David Milroy

David is a Partner at Maven Capital Partners where he is a member of Maven’s Investment Committee and is responsible for sourcing and executing private equity investments in Scotland as well as technology and life science investments across the UK. His current investments include Blacktrace Group, Curo Compensation, Optoscribe, QikServe, CB Technology and BioAscent. David started his career as a scientist with GlaxoSmithKline.

After completing his PhD, he moved to international consultancy firm Wood Mackenzie (and then parent Deutsche Bank) where he supported the healthcare banking team, advising clients on their corporate and licensing strategies; and performing due diligence projects on companies, products and technologies.

David joined Aberdeen Asset Management’s private equity division (spun-out to form Maven in 2009) in September 2007 as Fund Manager for an early-stage technology fund. David has a First Class Honours degree in Pharmacy, a PhD (Molecular Biology/Gene Delivery) from the University of Bath and a MBA from The University of Edinburgh.